Propanc Biopharma Secures Up to $100 Million in Private Placement from Hexstone Capital
Reuters
Nov 10, 2025
<a href="https://laohu8.com/S/PPCB">Propanc Biopharma</a> Secures Up to $100 Million in Private Placement from Hexstone Capital
Propanc Biopharma Inc. has announced it has entered into a securities purchase agreement with Hexstone Capital LLC for a private placement of up to $100 million in convertible preferred stock. The company received an initial investment of $1 million upon closing, issuing 100 shares of newly designated Series C Convertible Preferred Stock. In addition, Propanc will issue 9,900 warrants to Hexstone, each allowing the purchase of one share of preferred stock at $10,000 per share, providing up to $99 million in potential additional funding. The funds are intended to support Propanc's digital asset acquisition strategy and accelerate its R&D pipeline, with a focus on advancing its PRP therapy to a First-In-Human study in the second half of 2026. Further details are available in the company's Form 8-K filing with the SEC.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Propanc Biopharma Inc. published the original content used to generate this news brief on November 10, 2025, and is solely responsible for the information contained therein.
At the request of the copyright holder, you need to log in to view this content
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.